Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
The FDA is working with all six estradiol patch manufacturers to ramp up supply after a surge in demand left many women struggling to find the hormone therapy. Though no official shortage has been declared, patients have been pharmacy-hopping, switching brands, and adjusting doses. The agency is expediting reviews of supply-related submissions to help ease the crunch.
A surge in demand for estradiol transdermal patches — used to relieve menopause symptoms like hot flashes, mood swings, and sleep disturbances — has strained supplies and left many women scrambling to find them. The FDA says it's now actively working with all six manufacturers of the patches to boost production, even though it has stopped short of officially designating the situation as a formal shortage.
On the ground, the impact has been real: women are pharmacy-hopping, switching brands, reducing dosages, or pivoting to alternative therapies. The FDA notes that while availability may vary by pharmacy or location, estradiol transdermal patches are still technically on the market.
Key Takeaways:
Why it matters: Estradiol patches are a cornerstone of menopause hormone therapy for millions of women. Supply disruptions — even without a formal shortage label — can meaningfully disrupt care, pushing patients toward suboptimal alternatives or no treatment at all.
